Clinical Trials Logo

Azotemia clinical trials

View clinical trials related to Azotemia.

Filter by:

NCT ID: NCT01522183 Recruiting - Clinical trials for Atypical Hemolytic-Uremic Syndrome

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Start date: April 30, 2012
Phase:
Study type: Observational [Patient Registry]

Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.

NCT ID: NCT00531089 Recruiting - Clinical trials for Thrombotic Thrombocytopenic Purpura

Rituximab in Patients With Relapsed or Refractory TTP-HUS

Start date: December 2007
Phase: Phase 2
Study type: Interventional

The general objective of this study is to assess the efficacy and safety of Rituximab in the management of patients with refractory or relapsed thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS). There have been several case reports and case series describing the use of Rituximab in patients with TTP-HUS; however its use has not been studied in a large trial. It is hypothesized that Rituximab may ameliorate the severity of certain cases of TTP-HUS by decreasing the number of activity of B-cells which may result in decreased production of the ADAMTS13 protease inhibitor. Patients with TTP-HUS not responding to standard therapy or patients with relapsed disease may have particular benefit. Treatments that decrease the frequency of relapse or shorten the time to remission of TTP-HUS will be of benefit by decreasing the need for blood product support.